About ALS:

Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig’s disease, is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells (neurons) responsible for controlling voluntary muscles. The disease belongs to a group of disorders known as motor neuron diseases, which are characterized by the gradual degeneration and death of motor neurons. While about 5 percent of cases have been linked to a genetic mutation, generally there is no broadly accepted cause of ALS and only one, marginally effective therapeutic prescribed to combat it. Most people with ALS die from respiratory failure, usually within 3 to 5 years from the onset of symptoms. However, about 10 percent of ALS patients survive for 10 or more years. As many as 30,000 Americans have ALS at any given time, while the worldwide population is estimated at 400,000.

Dedication: Sean Forrester Scott

This annual report is dedicated to the memory of Sean Forrester Scott (1969-2009). On February 9, 2009, Sean, president of the ALS Therapy Development Institute died due to complications from amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). He was 39. Sean shared his final thoughts in an e-mail message to close friends and relatives composed shortly before his death:

“Just last year I was worried about turning 40. Now it appears I’ll never have the chance...It’s both surreal and horrifying to watch as muscles fail and with them skills that you spend a lifetime developing simply disappear. I’d trade every minute that I’ve got left for just one more chance to run across the tennis court and crack a forehand...I spent the last decade building an infrastructure to combat this disease. I had declared war on it but in the end it got me first. At a minimum, I think I earned the right to be referred to as KIA [killed in action] and not as a victim. I’d prefer that you remember me that way.”
At the ALS Therapy Development Institute, we are driven by a single, profoundly important goal – to discover viable treatments for ALS as quickly as possible.

**mission:** effective treatments to slow and stop ALS
ALS TDI: A Collaboration of Hope and Science for Today’s Patients

Mission: The mission of ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that stop ALS as soon as possible.

An Interdisciplinary Team
A staff of over 30 scientists and technicians work on behalf of ALS patients to discover and advance the best new ideas to stop ALS.

- RNA & Protein Validation
- Cell & Molecular Biology
- Computational Biology
- Analytical Chemistry
- In Vitro Validation
- In Vivo Validation
- Gene Expression
- Bioinformatics
- Pharmacology
- Histology

Focused on Finding Solutions
Amyotrophic Lateral Sclerosis = ALS (Lou Gehrig’s disease)

- 30,000+ ALS patients in the U.S.
- 350,000+ patients worldwide
- A new case every 90 minutes
- Incidence rate is about the same as Multiple Sclerosis
- No known cause, no known cure
A world-class research center, built by and for patients today, ALS TDI is the world's only non-profit biotechnology company with a single focus; stop ALS. With more than 30 professional scientists, the Institute is combating the disease like no one else.

With more than 30 professional scientists, the Institute is combating the disease like no one else.
Working with leaders in academia and industry is a central component of the comprehensive assault on ALS being undertaken at ALS TDI. Since the publication of the last annual report, the Institute cooperated with numerous organizations in order to advance the best therapeutics possible to slow and stop disease progression.

Specifically, the Institute developed strong collaborations with three industrial leaders – Microbix, Asklepios and Paragon to develop gene therapy constructs, based on changes in gene expression related to disease onset and progression that were identified through the Institute’s massive discovery biology effort. By working with some of the top viral vector manufacturers, ALS TDI is able to rapidly produce and move toward the validation of a gene therapy approach to slowing and stopping specific disease pathology.

Crucial clinical partnerships were entered into with a variety of top-tier ALS clinics, such as the Methodist Neurological Institute and the ALS and Neuromuscular Center at the UC Irvine Medical Center. These relationships opened the door for the collection of blood and other samples from ALS patients which could be analyzed for changes in gene expression levels and compared to data found in the animal model of disease. This work has led to the identification of many new target pathways and genes which the Institute is now developing therapeutics against.

Pictured left: These are just some of the partners that the ALS Therapy Development Institute works with to advance therapeutics through its rigorous drug development pipeline. These partners provide invaluable services to ALS TDI and play a key role in the development of therapeutics, genomic and proteomic information and research assistance. ALS TDI is proud to have these world-class organizations as its partners.
The Institute operates a robust discovery program and has the capacity to develop and rigorously validate therapeutics, including small molecules, gene therapies and cell based constructs. This approach to therapeutic development is unmatched in the ALS field.
Most scientists agree that a person’s propensity for developing a disease is a factor of both environment and genetics. While the figures vary slightly from publication to publication, it is commonly accepted that approximately 5-10% of ALS cases are inherited from generation to generation and can be linked to seemingly specific genetics. Of all these ALS cases, known as familial ALS, approximately 20% are caused by a genetic mutation which leads to the over expression of a mutant SOD1 enzyme.

Soon after this discovery in 1995 by a consortium of researchers, a sufficient model of disease was created through the breeding of genetically altered mice. This provided, for the first time, a viable preclinical model in which to screen, test and develop potential therapeutics. While the model was considered to be one of the most robust of its kind in the field of neurodegenerative research, problems still existed. The model’s use varied from lab to lab and little was known about how best to use it so that results from animal testing would mimic that which was seen in eventual clinical trials.

ALS TDI has the mission to develop effective therapeutics that slow and stop disease, and as such, when a drug was claimed by another laboratory to do just that the Institute had an obligation to the patient community that funds it to validate those findings. Unfortunately the opposite consistently happened both in the testing of drugs in the clinic and retesting of them at the Institute. This led to the identification of several statistically important variables (such as the number of animals used in the control and treatment groups) which when controlled for were shown to increase the likelihood that preclinical results would better match up with clinical results.

They are as follows:

**Number of Animals**
- at least 12 per group

**Litter Match**
- each treated male (and female) in the treatment group has a brother (and sister, respectively) in the control group

**Gender Match**
- same number of males and females in each group

**Copy Drift**
- all should have the same # of mutations confirmed before and after usage in study.

Caption: In 2008, ALS TDI scientists traveled to points domestic and abroad to share the importance of these findings with other research organizations, including a presentation at the 16th Annual MND/ALS International Research Symposium in Birmingham, England. The optimal efficacy study design is starting to be used by many organizations, and has been named by PRIZE4LIFE as a requirement of researchers entering its $1 million ALS biomarker contest.
In 2008, dozens of validation studies were conducted based on information garnered through internal discovery efforts as well as the continuous mining of data published by other laboratories.
A collision of experience and innovation takes place every Tuesday in the conference room at the Institute during the weekly “Portfolio and Project Update.” At any given time, there are dozens of different discovery biology and therapeutic validation studies taking place at the Institute. Rather than focusing on one aspect of disease, the Institute has built the ability to focus on everything at once. Everyday in the lab, researchers comb information on the expression of gene and proteins and mine data published by other research institutes. This information is analyzed and new projects proposed, debated and prioritized.

“Everyone on our team is a specialist in at least one area. We are organized so that there is a consistent flow of information between the core research groups. We are moving so fast at ALS TDI, it’s nearly impossible to stay current on everyone’s experiments. This meeting allows us to regroup each week, which is crucial in order to maintain our momentum.”

– JERRY DE ZUTTER, Ph.D., Team Leader, In Vitro Validation

“I’m not the first one to say that scientists can be rather disorganized. Project management isn’t just about kicking people in the butt, it’s about preventing bottlenecks and prioritizing.”

– BETH LEVINE, Project Management

“No one person owns a project at ALS TDI. Everyone on the research team has a chance to ask questions, suggest experiments and participate in the decision making process. This approach prevents our team from working in silos and encourages cross-communication, which often leads to the identification of key obstacles that need to be overcome at the beginning of a new project rather than half-way through.”

– STEVEN PERRIN, Ph.D., CEO/CSO
To execute their comprehensive scientific effort, the Cambridge, Massachusetts-based research institute collaborates with leaders in both academia and industry. In June 2009, ALS TDI launched a virtual tour of its research center which is now available online at www.als.net.
Recent Scientific Accomplishments

Over the past year, ALS TDI has made tremendous advances towards accomplishing its mission: developing effective therapeutics which slow and stop amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). The Research Staff at ALS TDI report progress to each other during regular New Lead and Project & Portfolio meetings, to the ALS Community via quarterly Research Update Webcasts, and to the Boards of Directors for ALS TDI, MDA and other funding organizations. Here are the top accomplishments which Research Staff reported on in 2008:

- ALS TDI 00846 – a biologic – Identified as Lead Therapeutic Candidate
- Reached or Surpassed All Scientific Milestones set by MDA in second year of $18 Million Grant
- Presented Optimal Efficacy Study Design to International ALS Organizations and Continued to Educate Other Laboratories and Researchers on its Use
- Expanded Gene Therapy Capabilities via Collaboration with Asklepios

The Research Pipeline at ALS TDI includes dozens of projects, each with the potential for developing into a lead therapeutic candidate and moving toward clinical trial. The Research Staff meets weekly to discuss progress on these projects, prioritize resources and debate the merits of adding or advancing additional potential therapeutics into the queue. For a complete glimpse of the Research Pipeline at ALS TDI, visit our website and select “Research Pipeline.”
About ALS:

Amyotrophic lateral sclerosis (ALS),
sometimes called Lou Gehrig's disease, is
a rapidly progressive, invariably fatal
neurological disease that attacks the nerve
cells (neurons) responsible for controlling
voluntary muscles. The disease belongs to
a group of disorders known as motor neuron
diseases, which are characterized by the
gradual degeneration and death of motor
neurons.

While about 5 percent of cases have been
linked to a genetic mutation, generally
there is no broadly accepted cause of ALS and
only one, marginally effective therapeutic
prescribed to combat it.

Most people with ALS die from respiratory
failure, usually within 3 to 5 years from the
onset of symptoms. However, about 10 percent
of ALS patients survive for 10 or more years.

As many as 30,000 Americans have ALS at any
given time, with a worldwide population
estimated at least 350,000.
Create Accessible, Open, Unbiased Lines of Communication for the Entire ALS Community

The ALS Therapy Development Institute was founded in 1999 with the idea that ALS patients should be put in the driver’s seat when it came to research. The Institute judges its success by the continuing development and evolution of new programs to empower and involve the ALS community in research through a broad network of Informational Programs, such as its successful ALS Research 101 Seminar. Whether it be the traditional in-person meeting with a group of pALS and cALS or an online discussion via webinar or webcast, these Informational Programs are specifically designed to foster two-way communication between ALS patient and ALS researcher. Here are the numbers for participation for the most recent year:

ALS Research 101 Seminar

205 people attended 10 different seminars in cities across the United States throughout the year. These seminars were created by John McCarty, Ph.D. and were co-led by the Institute’s regional staff. The interactive 2-hour discussion focused on describing in detail the drug development process, bridging the translational research gap and answering questions about the clinical trial process.

Introduction to ALS Research Monthly Webinars

ALS TDI broke ground in the ALS research world by committing to and holding a monthly webinar with ALS patients and their family members. During this 30-minute, 20-slide presentation, online viewers were introduced to the basic premises of ALS research, asked questions on the latest advancements and interacted directly with a variety of research staff at ALS TDI.

ALS Community Research Update Webcast

Sean Scott, President of ALS TDI, hosted the first of three conference calls in February of 2008. The second and third were held in July and December respectively. On average, 200 people joined Sean, Steve Perrin, Ph.D., and John McCarty, Ph.D. for a discussion on progress at ALS TDI and elsewhere toward effective therapeutics to slow or stop ALS. The December update was broadcast via the same webcast system as the Summit, streaming live audio and video to the web.

4th Annual Leadership Summit

Last year, ALS patient Jeff Cronon challenged ALS TDI to find a way to make its Leadership Summit more accessible to patients that could not afford to travel to Cambridge themselves. And found a way we did; by webcasting 4-hours of the event’s scientific presentations and panel discussion (Stan Appel, M.D., Sharon Hesterlee, Ph.D., Jean-Pierre Julien, Ph.D., Michael Strong, M.D., and Steve Perrin, Ph.D.). In addition to the 150 people that participated in person for a Lab Tour and the Research Symposium, more than 400 people from around the world turned in for some portion of the webcast. They were treated to significant updates from ALS TDI, including the introduction of its lead candidate molecules.
The ALS Therapy Development Institute is the world's first non-profit biotechnology company. As such, we combine the best practices of industrial scale, world-class research organization with the focus and power of a nonprofit mission. An important part of our strategy for success is to leverage the knowledge and passion of the ALS Community in order to advance our shared vision for a future where ALS can be stopped. Therefore, the Institute has created the most comprehensive open-communication programs in the whole of the ALS field - all of which are offered free of charge and to the entire ALS Community.
Hope and inspiration are everywhere on ALSCommunity.org. There are currently 150 different families that have set up their own page and presence and ALS TDI has a goal of doubling that number by the end of 2009. Each and every member of the ALS community – patients, caregivers, friends, employers – has a role to play in making a world where ALS can be stopped a reality. By providing a place for all these people and corporations to come together, ALSCommunity.org is designed to harness the power of online social networking and create a vibrant web-based machine which will inspire and empower all.
ALS TDI reports its progress and accomplishments directly to the ALS community in a variety of venues:

- ALS Research 101 (a traveling seminar)
- Responding to the ALS Crisis (a monthly webinar)
- The ALS Forum (an online discussion board)
- Leadership Summit & Open House (annual research symposium)
In 2008, the ALS Therapy Development Institute was the recipient of grants from two major funders; The RGK Foundation and the Muscular Dystrophy Associations’ Augie’s Quest. These forward thinking organizations provided key commitments and crucial unrestricted funding which enabled ALS research to advance quicker than ever before. The involvement of these organizations doesn’t end with the writing of a check however; they stay involved in key decision making at the Institute and receive regular, detailed updates from the Institute’s top research team members.

About MDA’s Augie’s Quest

Curing ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) requires dismantling the disease gene by gene and protein by protein. Armed with this information, research will finally have the ammunition needed to develop highly targeted therapeutics to slow, stop and arrest the disease. Augie’s Quest is an aggressive, cure-driven effort singularly focused on finding treatments and cures for ALS. As an initiative of the Muscular Dystrophy Association and the MDA’s ALS Division, Augie’s Quest is recognized as a world leader in providing funding and raising awareness of the fatal neurodegenerative disease which strikes a new person every 90 minutes in the United States alone. ALS TDI and MDA/AQ have been partners in scientific, outreach and fundraising efforts since 2007 – encompassing a $36 million joint research effort – the largest of its kind in the world.

About the RGK Foundation

The RGK Foundation is an independent foundation established in 1966 by Ronya and George Kozmetsky. The RGK Foundation endeavors to be a catalyst for progressive change in humanitarian concerns. Guiding the Foundation is a deep reverence for democracy and a civil society together with the founders’ values of foresight, imagination and discovery. By seeking innovative projects in the area of health, education, human services and community affairs, the Foundation strives to advance knowledge, improve society and help realize human potential. The RGK Foundation has been a long-time partner and supporter of ALS TDI, enabling its growth over the past decade to become the world’s leading ALS research effort. In 2008, the RGK Foundation renewed its confidence in ALS TDI with a gift of $1 million.
ALS TDI is a 501c3 registered non-profit organization. Our tax identification number is 04-3462719. As a non-profit organization built by and for ALS patients, ALS TDI takes great pride in being as transparent as possible. The Institute provides more detailed information about its research, fundraising and expenses than most similar organizations. In fact, all of ALS TDI's financial and annual reports are available via its website at www.als.net/aboutus.

Donations to ALS TDI are tax-deductible.
Passionate Leadership Renews ALS TDI

A new Chief Executive Officer, President and Board Member were named during this past Annual Meeting of the Board of Directors of the ALS Therapy Development Institute. The Board was provided updates on the Institute's fundraising efforts, research and development advances and overall performance toward accomplishing its mission – the creation of effective treatments to slow and stop ALS (amyotrophic lateral sclerosis, commonly known as Lou Gehrig's disease). The board works closely with the executive team at ALS TDI to ensure that the maximum amount of funding is spent on research. For more information on the Institute’s finances in 2008, please see the next two pages of this Annual Report. The following appointments were made:

Ted Reich, CPA – Appointed Board Member

An experienced lawyer and C.P.A., Mr. Reich is a partner at Reich and Walner LLP of Oakland, California. Ted’s son Corey 22 (picture to right) was diagnosed with ALS in October 2007. The Reich family has raised more than $700,000 for research since then, and has been very active in their local ALS community. With his appointment, Mr. Reich became the 12th voting board member of the world's largest non-profit biotech. A full list of the board is provided on the back cover of this Annual Report.

Steven Perrin, Ph.D. – Appointed Chief Executive Officer

As chief executive officer and chief scientific officer at ALS TDI, Steve Perrin, Ph.D., is responsible for ensuring the Institute continues to advance its mission to discover and develop effective therapeutics for ALS. Dr. Perrin is an expert in the drug development process and has nearly two decades of experience in leading preclinical and translational research efforts. Since coming to ALS TDI in 2007, Dr. Perrin has added new capabilities to the Institute's drug development pipeline, which now includes small molecules, gene therapy, protein biologics and stem cell projects.

Maureen A. Lister – Appointed President

Maureen Lister, a corporate operations and finance expert with experience in the biomedical and high tech industries, joined ALS TDI in the spring of 2007 as its chief financial officer and was named chief operating officer in 2008. Under Mrs. Lister's leadership, ALS TDI has increased its fundraising revenue to new highs in each of the last two years. The Institute has also substantially increased the percentage it spends on research, the largest in the field, by focusing on creating more efficient administrative and fundraising operations under Mrs. Lister's guidance.
A world-class scientific research center, built by and for ALS patients, ALS TDI is a nonprofit biotechnology company that combines the proven methods and best practices used in industry with the passion of a nonprofit mission. Our research team is executing the largest discovery biology and drug development project possible today to combat ALS.
2008: MAJOR GIFTS AND GRASSROOTS FUNDRAISING DRIVING FORCES BEHIND BEST YEAR YET

For the fiscal year ending December 31, 2008, ALS TDI recognized more than $11 million in public support and unrestricted revenue. **2008 REPRESENTED THE INSTITUTE’S SINGLE LARGEST FUNDRAISING YEAR TO DATE.** This support came from a variety of sources, including more than $8.5 million from grants and contracts, $2.2 million in net contributions from individuals and grassroots fundraising efforts. A full break-down of unrestricted revenue, assets and expenses is below. New revenues led to the expansion of resources available at ALS TDI and most importantly **NEARLY $2 MILLION ADDITIONAL SPENT ON ITS SCIENCE PROGRAM.** In addition, the ALS TDI continued its trend of reducing the percentage of revenues spend on fundraising and administrative efforts leading to the **HIGHEST RATIO OF SPENDING ON EXECUTING ITS PRIMARY PROGRAM IN HISTORY – NEARLY 87%**

(all figured below are in whole u.s. dollars)

<table>
<thead>
<tr>
<th>Assets</th>
<th>FY2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>2,775,559</td>
</tr>
<tr>
<td>Accounts &amp; Pledges Receivable</td>
<td>83,911</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>117,094</td>
</tr>
<tr>
<td>Investments</td>
<td>5,302</td>
</tr>
<tr>
<td>Fixed Assets (Net)</td>
<td>885,612</td>
</tr>
<tr>
<td>Other Assets (Net)</td>
<td>205,632</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>4,073,110</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities &amp; Net Assets</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Liabilities</td>
<td>1,124,695</td>
</tr>
<tr>
<td>Total Net Assets</td>
<td>2,948,415</td>
</tr>
<tr>
<td><strong>Total Unrestricted Liabilities and Net Assets</strong></td>
<td><strong>4,073,110</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Public Support and Revenues</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Grants &amp; Contracts</td>
<td>8,520,361</td>
</tr>
<tr>
<td>Special Events &amp; Contributions (Net)</td>
<td>2,034,534</td>
</tr>
<tr>
<td>General Contributions</td>
<td>192,738</td>
</tr>
<tr>
<td>Donated Good &amp; Services</td>
<td>218,973</td>
</tr>
<tr>
<td>Interest and Other</td>
<td>55,426</td>
</tr>
<tr>
<td><strong>Net Public Support and Revenues</strong></td>
<td><strong>11,022,032</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>FY2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Program Services</strong></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Development</td>
<td></td>
</tr>
<tr>
<td>Science Programs</td>
<td>5,242,507</td>
</tr>
<tr>
<td>Lab</td>
<td>1,888,703</td>
</tr>
<tr>
<td>Informatics</td>
<td>317,711</td>
</tr>
<tr>
<td>Patient Services</td>
<td>473,104</td>
</tr>
<tr>
<td>Clinical</td>
<td>41,170</td>
</tr>
<tr>
<td>Communications</td>
<td>793,519</td>
</tr>
<tr>
<td>Business Development</td>
<td>262,092</td>
</tr>
<tr>
<td><strong>Total Program Services</strong></td>
<td><strong>9,018,806</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Support Services</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>General &amp; Administrative</td>
<td>779,624</td>
</tr>
<tr>
<td>Fundraising</td>
<td>576,250</td>
</tr>
<tr>
<td><strong>Total Support Services</strong></td>
<td><strong>1,355,874</strong></td>
</tr>
</tbody>
</table>

| **Total Expenses** | 10,374,680 |

ALS Therapy Development Institute is a Federally Registered Non-Profit Organization. Our Tax-Exempt (EIN) is 043462719. Additional state-specific tax-exemption information available upon request.
2008: Nearly $2 million more raised and spent on research than the year before

Each year, ALS TDI judges its success by a single measure - are we closer to an effective therapeutic that before? In 2008, the Institute received more support in a single year than any year previously - translating into tremendous growth in spending in its science programs overall. In addition, the Institute was able to generate more fundraising leads than every before by creating new and empowering communication programs designed to reach the entire ALS community. In addition, the Institute continued to lower the ratio per dollar spent on fundraising - the lowest percentage in the history of the organization. A growing network of passionate and active supporters kept costs down.

These are just numbers on a piece of paper, important numbers they are. However - are we closer to achieving our mission? In 2008, at the 4th Annual Leadership Summit held along the banks of the Charles River in Boston, Dr. Steven Perrin, Chief Scientific Officer of ALS TDI announced that the Institute has discovered a molecule of great interest. The molecule, known only as ALS TDI 00846, had been identified by ALS TDI researchers to slow progression of disease, slow loss of body weight and overall increase survival in preclinical testing.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Program Services</strong></td>
<td><strong>2008</strong></td>
<td><strong>2007</strong></td>
<td><strong>2006</strong></td>
<td><strong>2005</strong></td>
</tr>
<tr>
<td>Research &amp; Development</td>
<td>$5,242,507</td>
<td>$3,137,983</td>
<td>$2,024,445</td>
<td>$1,162,466</td>
</tr>
<tr>
<td>Science Programs</td>
<td>50.53%</td>
<td>40.07%</td>
<td>26.13%</td>
<td>31.12%</td>
</tr>
<tr>
<td>Lab</td>
<td>$1,888,703</td>
<td>$2,024,445</td>
<td>$1,443,998</td>
<td>$1,214,299</td>
</tr>
<tr>
<td>Informatics</td>
<td>317,711</td>
<td>405,878</td>
<td>353,370</td>
<td>150,697</td>
</tr>
<tr>
<td>Patient Services</td>
<td>4.56%</td>
<td>4.83%</td>
<td>4.04%</td>
<td>5.20%</td>
</tr>
<tr>
<td>Clinical</td>
<td>41,170</td>
<td>24,575</td>
<td>29,859</td>
<td>48,814</td>
</tr>
<tr>
<td>Communications</td>
<td>793,519</td>
<td>504,352</td>
<td>423,584</td>
<td>237,336</td>
</tr>
<tr>
<td>Business Development</td>
<td>262,092</td>
<td>256,333</td>
<td>167,230</td>
<td>131,821</td>
</tr>
<tr>
<td>Total Program Services</td>
<td>$9,018,806</td>
<td>$6,753,617</td>
<td>$4,314,971</td>
<td>$3,139,699</td>
</tr>
<tr>
<td><strong>Support Services</strong></td>
<td><strong>2008</strong></td>
<td><strong>2007</strong></td>
<td><strong>2006</strong></td>
<td><strong>2005</strong></td>
</tr>
<tr>
<td>General &amp; Administrative</td>
<td>$779,624</td>
<td>$581,598</td>
<td>$337,848</td>
<td>$221,201</td>
</tr>
<tr>
<td>Fundraising</td>
<td>5.55%</td>
<td>7.44%</td>
<td>6.65%</td>
<td>5.93%</td>
</tr>
<tr>
<td>Total Support Services</td>
<td>$1,355,874</td>
<td>$1,077,150</td>
<td>$757,196</td>
<td>$595,320</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>$10,374,680</td>
<td>$7,830,767</td>
<td>$5,072,167</td>
<td>$3,735,019</td>
</tr>
</tbody>
</table>

The ALS Therapy Development Institute (ALS TDI) is a registered 501(c)3 non-profit charitable organization. For complete financial information, please contact Maureen Lister, President, 617-441-7200.
Each member of the ALS TDI team brings with them passion, experience and commitment to success. Your membership in Leadership Giving Circle helps to ensure that our scientists have the critical resources they need. This is your lab; you are an important part of the team. Each member is recognized on the ALS TDI website, in the Annual Report and the Leadership Summit Guidebook.

### Research Champion ($25,000 or more)

<table>
<thead>
<tr>
<th>Name</th>
<th>Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALS Family Charitable Foundation Inc</td>
<td>ALS Family Charitable Fund</td>
</tr>
<tr>
<td>Anonymous</td>
<td>Sean Forrester Scott Fund</td>
</tr>
<tr>
<td>Cohen and Malad, LLP</td>
<td>Steve Milne Effort</td>
</tr>
<tr>
<td>Dick and Dawn Sanderson Fund</td>
<td>HMS Host Fund</td>
</tr>
<tr>
<td>Help America Foundation</td>
<td>Corey Reich Fund</td>
</tr>
<tr>
<td>HMS Host Invitational</td>
<td>Friends for Faye Fund</td>
</tr>
<tr>
<td>Insource Services, Inc.</td>
<td></td>
</tr>
<tr>
<td>Javier and Rose Burillo</td>
<td></td>
</tr>
<tr>
<td>KeyBank National Association</td>
<td></td>
</tr>
<tr>
<td>Muscular Dystrophy Association</td>
<td></td>
</tr>
</tbody>
</table>

### Research Champion continued

<table>
<thead>
<tr>
<th>Name</th>
<th>Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parksburg Area Area</td>
<td></td>
</tr>
<tr>
<td>Community Foundation</td>
<td></td>
</tr>
<tr>
<td>Randy Craft</td>
<td></td>
</tr>
<tr>
<td>RGK Foundation</td>
<td></td>
</tr>
<tr>
<td>Sierra Pacific Foundation</td>
<td></td>
</tr>
<tr>
<td>The James and Alice McGonagle Charitable Fund</td>
<td></td>
</tr>
<tr>
<td>The Jeff Julian ALS Foundation</td>
<td></td>
</tr>
<tr>
<td>Theodore and Wendy Reich</td>
<td></td>
</tr>
</tbody>
</table>

### Research Visionary ($10,000 - $24,999)

<table>
<thead>
<tr>
<th>Name</th>
<th>Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>A and B Markstein Foundation</td>
<td>Corey Reich Fund</td>
</tr>
<tr>
<td>A Midwinter Night Dream</td>
<td>Northport High School Fund</td>
</tr>
<tr>
<td>Ahrens and DeAngelii PLLC</td>
<td>Corey Reich Fund</td>
</tr>
<tr>
<td>Ann Arbor Active Against ALS</td>
<td>Ann Arbor Active Against ALS Fund</td>
</tr>
<tr>
<td>ASD Foundation</td>
<td>Corey Reich Fund</td>
</tr>
<tr>
<td>Barbee Rubenstein</td>
<td>Corey Reich Fund</td>
</tr>
<tr>
<td>Bay Alarm Fund c/o East Bay Community Foundation</td>
<td></td>
</tr>
<tr>
<td>Buffalo Renaissance Foundation</td>
<td></td>
</tr>
<tr>
<td>Chris Stoikos Memorial</td>
<td></td>
</tr>
<tr>
<td>Dellabarca Design and Build, Inc</td>
<td></td>
</tr>
<tr>
<td>Doug and Ellen Reich</td>
<td></td>
</tr>
<tr>
<td>Fran Delaney Foundation</td>
<td></td>
</tr>
<tr>
<td>Gerald and Virginia Davidson</td>
<td></td>
</tr>
<tr>
<td>Healthport Technologies</td>
<td></td>
</tr>
<tr>
<td>Ian and Sandra Mullinch</td>
<td></td>
</tr>
<tr>
<td>Jeremy Blackburn</td>
<td></td>
</tr>
<tr>
<td>John Hecht</td>
<td></td>
</tr>
<tr>
<td>Keith and Jil Melanson</td>
<td></td>
</tr>
<tr>
<td>Kendra Keating</td>
<td></td>
</tr>
<tr>
<td>Larry and Susan Ricksen</td>
<td></td>
</tr>
<tr>
<td>Mark Emmerson</td>
<td></td>
</tr>
<tr>
<td>Matt White Cure ALS Foundation Inc</td>
<td></td>
</tr>
<tr>
<td>Moglia Family Foundation</td>
<td></td>
</tr>
<tr>
<td>Mr and Mrs Wynne Gulden Jr</td>
<td></td>
</tr>
<tr>
<td>New Jersey PGA</td>
<td></td>
</tr>
<tr>
<td>Nokia Inc.</td>
<td></td>
</tr>
<tr>
<td>Phil Kramer Fund</td>
<td></td>
</tr>
</tbody>
</table>

### Research Visionary continued

<table>
<thead>
<tr>
<th>Name</th>
<th>Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olson ALS Foundation INC</td>
<td>Olson ALS Fund</td>
</tr>
<tr>
<td>Radiology, Inc.</td>
<td>Friends for Faye Fund</td>
</tr>
<tr>
<td>Reich and Walner LLP</td>
<td>Corey Reich Fund</td>
</tr>
<tr>
<td>Richard Tucker</td>
<td>Jeff Cronon Fund</td>
</tr>
<tr>
<td>Richard W Rupp Foundation Inc</td>
<td>Margaret Roblin Fund</td>
</tr>
<tr>
<td>Ride For Life</td>
<td></td>
</tr>
<tr>
<td>Riverview Medical Center</td>
<td></td>
</tr>
<tr>
<td>Roby and Nadja Molnar</td>
<td></td>
</tr>
<tr>
<td>Russ and Sara Foszcz</td>
<td></td>
</tr>
<tr>
<td>Steven Berger</td>
<td></td>
</tr>
<tr>
<td>Stillwell Hansen Inc</td>
<td></td>
</tr>
<tr>
<td>Storyzon, LLC</td>
<td></td>
</tr>
<tr>
<td>Taylor Fresh Foods Inc</td>
<td></td>
</tr>
<tr>
<td>The MBK Foundation</td>
<td></td>
</tr>
<tr>
<td>The Thorson Foundation</td>
<td></td>
</tr>
<tr>
<td>The Torretta Foundation</td>
<td></td>
</tr>
<tr>
<td>Tim Blaskovich</td>
<td></td>
</tr>
<tr>
<td>Tom and Paula Keating</td>
<td></td>
</tr>
<tr>
<td>Toni and Don Loback</td>
<td></td>
</tr>
<tr>
<td>Warner Bros. Entertainment Inc</td>
<td></td>
</tr>
<tr>
<td>Westhaven Charities Inc</td>
<td></td>
</tr>
<tr>
<td>Westphal Family Foundation</td>
<td></td>
</tr>
<tr>
<td>William and Suzy Vogler</td>
<td></td>
</tr>
</tbody>
</table>

### Research Visionary continued

<table>
<thead>
<tr>
<th>Name</th>
<th>Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Blaschow Fund</td>
<td></td>
</tr>
<tr>
<td>Corey Reich Fund</td>
<td></td>
</tr>
<tr>
<td>Friends for Faye Fund</td>
<td></td>
</tr>
<tr>
<td>Steve Greenspan Fund</td>
<td></td>
</tr>
<tr>
<td>Corey Reich Fund</td>
<td></td>
</tr>
<tr>
<td>Corey Reich Fund</td>
<td></td>
</tr>
</tbody>
</table>

### Research Visionary continued

<table>
<thead>
<tr>
<th>Name</th>
<th>Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corey Reich Fund</td>
<td></td>
</tr>
<tr>
<td>Jenny Stoddard Fund</td>
<td></td>
</tr>
</tbody>
</table>
Research Steward ($5,000 - $9,999)

Name
ALS Benefit Account
Bergan Mercy Medical Staff
Boulder Peak LLC
Burkhardt Advertising Inc
Connecticut Friends For ALS Research
Core Network, LLC
Credit Suisse Americas Foundation mini program
Daniel and Theresa Walner
Darwin and Dorothy Wiekamp
David and Jessica Antal
David and Mitzi Sabato
David Brason
Dennis and Patricia-Ann Bourassa
Doty Family Foundation
Doug Cotter
Enterprise
Frank Murphy
Frey Electric Construction
Friends of Jim Hughes
Gary Brost
Health Plan of Nevada
Hilary Jordan
Indiana State Seniors Golf Assoc
ITW Foundation
James Herbert
Jeff Redman
Jennifer Huntington
Jim Marshall
John and Beverly Cline
John and Mary Ricksen
Karen Regensdorfer
Ledge Light Federal Credit Union
Leslie Wilper
Lower Falls Wine Company
Marilyn Adams
Memorial Health System
Nelson Cambata

Fund
Anthony Tucker Fund
Mark Christensen Fund
5430 Sports Fund
Friends for Faye Fund
Eliot Macht Fund
Gloria Tourk Effort
Manhattan Fund
Corey Reich Fund
Friends for Faye Fund
Big G Fund
Friends for Faye Fund
Margaret Robin Fund
Bourassa Fund
Corey Reich Fund
Jeff Cronon Fund
Steve Milne Effort
Jeff Cronon Fund
Margaret Robin Fund
Jim Hughes Fund
Margaret Robin Fund

Research Steward continued

Name
New Era Cap Co Inc
Nutter, McClennen and Fish LLP
Pamal Broadcasting LTD
Patricia Lee
Peter Colichidas
Polo Ralph Lauren Foundation
Potter General Inc
Richard and Vivian Douglass
Richard Portewig
Robert and Alice Butler Family
Charitable Foundation
Robert and Lila Tickman
Roger and Beverly Freeman
Rubin Kuznetsky
Saint Joseph RMC Inc
Sand Creek
Sid Theus
Susan A Kireker Memorial Trust
Taylor Family Investments LLC
The Stanfield Foundation
The Stella Matutina O’Connor Foundation
Thomas S. Watson Family Foundation
William Huntress
William and Betsy Leitch
William Hungerford
Woodbine Bend Inc.
Woodward

Fund
Corey Reich Fund
Peter Colichidas Fund
Jeff Cronon Fund
Dick Douglass Effort
Corey Reich Fund
Jennifer Nichols Fund
Herb Schwartz Fund
Corey Reich Fund
Rubin Kuznetsky Fund
Friends for Faye Fund
Rubin Kuznetsky Fund
Jeff Cronon Fund
Corey Reich Fund
Stanfield Family ALS Research Fund
Mary Lou Krauseneck Fund
Margaret Robin Fund
Stephen Heywood Fund
Margaret Robin Fund
Jenny Stoddard Fund
Scott McWhorter Fund

Research Sponsor ($1,000 - $2,499)

Name
The Health Club at Southpointe
The Law Offices of Fischer, Garon, Hoyumpa & Rancilio
The Osprey Foundation
The Overaa Family Group
The Philanthropic Fund
The Reichert Foundation
The Schwartz Living Trust
The Stodder Family
Therese Deegan
Thomas and Elizabeth Phelps
Thomas and Jordan Kraus
Thomas and Robin Reveli
Thomas Austin
Thomas Callahan
Thomas Shambo
Thomas Wagner
Timothy Thill
Tom and Brightte Reich
Tom and Susan Fischbach
Troco Oil Company
US Energy Corporation
Valparaiso Country Clubs Inc
Walt & Linda Tucker
Wasserman Company
WD and HH Jennings
Wendy Winnick-Baskin
William Cole
William Fick and Trench Plate
William Jenkins
William Robbins
William Scott
Wings Air
Wirelessone

Fund
Pittsburgh Families Effort
Mary Lou Krauseneck Fund
John Yost Memorial Fund
Corey Reich Fund
Margaret Robin Fund
Corey Reich Fund
Jenny Stoddard Fund
Jeff Cronon Fund
Corey Reich Fund
Team Calhoun
Joe Shambo Fund
Margaret Robin Fund
Margaret Robin Fund
Corey Reich Fund
Stanfield Family ALS Research Fund
Rubin Kuznetsky Fund
Anthony Tucker Fund
HMS Host Fund
Phil Kramer Fund
Margaret Robin Fund
Corey Reich Fund
Orange County Fund
Ken Melanson Fund
Corey Reich Fund
Margaret Robin Fund
Phil Kramer Fund

Research Advocate ($2,500 - $4,999)

Name
Robert Stevenson
Ron Sacco
Roura and Melamed Attorney’s at Law
Sharing Hope Foundation
Steamboat Springs Triathlon
Stephen and Bernardette Cooper
Stephen Peckiconis and Dona Nicholas
Steven and Linda Bauersachs
Steven Root
Stuart and Anne Knowles
Susan Justice
T.J.Wesley Ill
The Bay State Federal Savings
The Delta Interests LLC
The Demakos Foundation
Timothy Geiger
Todd Brason
Tracy Leonard
TTM Holdings LLC
Turner Oil and Gas Properties
University of Pittsburgh Medical Center
Vanguard Charitable Endowment Program
Wells Fargo Investments, LLC
William and Kathy Raftery

Fund
Margaret Robin Fund
5430 Sports Fund
Linda Bauersachs Fund
Margaret Robin Fund
Margaret Robin Fund
Margaret Robin Fund
Pam Callahan Fund
Jeff Cronon Fund
Stanfield Family ALS Research Fund
Pam Callahan Fund
Friends for Faye Fund